Answers are grounded in this paper and cite their sources.
Extracorporeal membrane oxygenation (ECMO) is a technique developed to ensure adequate tissue oxygen delivery in patients suffering cardiac and/or respiratory failure. ECMO can provide this delivery without causing the iatrogenic damage associated with high mechanical ventilation pressures, high fraction of inspired oxygen, or high doses of inotropic medications. Though practitioners use a multitude of other, more "conventional," therapies for neonatal respiratory failure, only ECMO has been proven in a randomized, controlled, clinical trial to improve both mortality and morbidity among neonates. Though a randomized controlled trial of ECMO in the neonate has been published, to date no trial in the pediatric, adult, or cardiac population is complete. The Extracorporeal Life Support Organization registry provides data on the over 20,000 ECMO cases performed to date and serves as a resource to refine this supportive therapy. This support is not without complications, and it should be used in appropriate populations, with specific criteria for initiation.
No takes yet. Share an insight, caveat, or question.
Douglas R Hansell (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: